知镜 Cognispect · 医学文献与研究工作台

Posttransfusion Management of RhD-Negative Females of Childbearing Potential Who Receive RhD-Positive Low-Titer Group O Whole Blood and RBCs During Trauma Resuscitation: A Joint Position Statement and Resource Document of the American College of Surgeons Committee on Trauma, Prehospital Blood Transfusion Coalition, National Association of Emergency Medical Services Physicians, Trauma Hemostasis and Oxygenation Research Network, and Allo Hope Foundation.

Henry R, Coleman JR, Holcomb JB, Lammers D, Raykar N, Hashmi ZG, Schaefer R, Mackey K, Ernest E, Rimsza R, Sherwood M, Spinella PC, Barrett CD, Cannon JW, Schreiber MJ, Yazer MH.
Journal of the American College of Surgeons · 2026-11-13 · PMID 42490058

文献摘要

Background Increasing use of low-titer group O whole blood and RBC in trauma resuscitation has increased the likelihood that RhD-negative females of childbearing potential (FCPs) will receive RhD-positive blood products. Concurrently, national trauma data demonstrate that FCPs with traumatic hemorrhage are approximately 40% less likely to receive low-titer group O whole blood than comparable male patients, highlighting a trauma systems and equity concern. Evidence-based guidance for posttransfusion management remains limited. Study design A multidisciplinary panel representing trauma surgery, transfusion medicine, emergency medicine, critical care, OB, pediatrics, and prehospital care reviewed available literature, registry data, modeling studies, existing guidance, and ethical considerations and developed consensus recommendations through an iterative process for management of RhD-negative FCPs exposed to RhD-positive blood products during trauma resuscitation. Results Reported D-alloimmunization rates after trauma transfusion range from approximately 8% to 43%. Modeling studies estimate a perinatal death risk from anti-D-mediated hemolytic disease of the fetus and newborn (HDFN) of approximately 0.04% and a combined severe HDFN and perinatal death risk of approximately 0.24% after RhD-positive transfusion. Estimated risk of any HDFN-complicated future pregnancy ranges from approximately 0.6% to 6.5%. The panel concluded that RhD-positive blood products should not be withheld when RhD-negative products are unavailable, and transfusion is clinically indicated. Recommended management includes selective Rh immunoglobulin prophylaxis for low-volume exposures, structured antibody surveillance, patient counseling, multidisciplinary follow-up, and institutional protocols. Conclusions For RhD-negative FCPs with life-threatening hemorrhage, immediate survival should take precedence over potential future reproductive risk. Standardized posttransfusion pathways may support equitable access to lifesaving transfusion while mitigating alloimmunization-related reproductive risks.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。